Biology of the Radiotheranostic Approach
Alberto Vargas, MD, offers an in-depth exploration of theranostics in oncology, focusing on prostate cancer.
Read More
2024
Use of AI to Develop Training Platforms: Is Big Brother Watching?
Nelson N. Stone, MD, explores artificial intelligence (AI) and its potential role in surgical education and training.
Read More
AI and Machine Learning: What the Future Holds
Sigrid V. Carlsson, MD, PhD, MPH, discusses artificial intelligence (AI) and machine learning in medicine and urology.
Read More
How AI Improves Imaging Interpretation
Alberto Vargas, MD, examines the integration of AI into prostate MRI, focusing on its current state, challenges, and future implications. In this 19-minute presentation, Dr. Vargas shares that current AI in prostate MRI aims to match the diagnostic accuracy of expert radiologists rather than surpass it, addressing challenges such as subjective variability in radiologist reports and optimization of workflow efficiency.
Deep learning, a subset of AI, emerges as the most promising approach, but concerns linger about its interoperability and blind spots. Ethical considerations are critical, especially the risk of creating unequal access to AI-driven diagnostics. The presentation also stresses the importance of user-friendly software integration within existing imaging platforms.
Dr. Vargas emphasizes the necessity of demonstrating value through improved patient outcomes and experiences. He takes a forward-looking perspective on AI’s evolving role in prostate MRI, balancing optimism with realistic expectations.
Read More
CAPTAIN: A Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation of the Prostate versus Radical Prostatectomy
Xiaosong Meng, MD, PhD, explores the ongoing CAPTAIN trial, a multinational, randomized clinical study comparing transurethral ultrasound ablation (TULSA) with radical prostatectomy in patients with intermediate-risk prostate cancer. The CAPTAIN trial builds on the TACT study, which demonstrated the safety and efficacy of whole-gland ablation using TULSA.
In this 11-minute presentation, Dr. Meng outlines the eligibility criteria for the CAPTAIN trial participants and reviews the study schema. The trial aims to provide level 1 evidence of safety and efficacy, addressing the need for robust comparative studies to support guideline adoption of ablative technologies.
The trial evaluates outcomes including quality of life, urinary continence, erectile function, and long-term efficacy, with follow-up extending to 10 years. The study’s findings are anticipated to substantiate the use of TULSA as an effective and patient-preferred alternative to radical prostatectomy, potentially influencing clinical practice and reimbursement policies.
Read More